HC Wainwright Has Bearish Outlook for Erasca FY2027 Earnings

Erasca, Inc. (NASDAQ:ERAS) – Equities research analysts at HC Wainwright decreased their FY2027 earnings estimates for shares of Erasca in a research note issued on Monday, January 26th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($0.50) for the year, down from their prior forecast of ($0.40). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Erasca’s current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Erasca’s FY2028 earnings at ($0.55) EPS, FY2029 earnings at ($0.55) EPS and FY2030 earnings at ($0.37) EPS.

Several other brokerages also recently commented on ERAS. Morgan Stanley set a $10.00 price objective on shares of Erasca in a research report on Monday. Stifel Nicolaus set a $10.00 target price on Erasca in a research report on Monday, January 12th. Mizuho started coverage on shares of Erasca in a report on Tuesday. They set an “outperform” rating and a $16.00 price objective for the company. Guggenheim restated a “buy” rating and issued a $12.00 target price on shares of Erasca in a report on Tuesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Erasca in a research note on Thursday, January 22nd. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $9.22.

Erasca Stock Performance

ERAS stock opened at $10.50 on Wednesday. Erasca has a 52-week low of $1.01 and a 52-week high of $10.67. The firm has a market capitalization of $3.25 billion, a price-to-earnings ratio of -23.33 and a beta of 1.15. The firm has a 50 day moving average price of $4.91 and a 200-day moving average price of $2.97.

Erasca (NASDAQ:ERAS) last announced its earnings results on Wednesday, November 12th. The company reported ($0.11) EPS for the quarter, meeting analysts’ consensus estimates of ($0.11).

Insider Activity

In related news, General Counsel Ebun Garner sold 120,000 shares of the business’s stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $5.59, for a total transaction of $670,800.00. Following the completion of the transaction, the general counsel owned 25,076 shares in the company, valued at $140,174.84. The trade was a 82.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 14.40% of the stock is owned by company insiders.

Institutional Trading of Erasca

Several hedge funds have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Erasca by 25.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,787 shares of the company’s stock valued at $51,000 after acquiring an additional 2,820 shares in the last quarter. Captrust Financial Advisors increased its position in shares of Erasca by 13.6% in the second quarter. Captrust Financial Advisors now owns 54,111 shares of the company’s stock valued at $69,000 after buying an additional 6,486 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in Erasca by 58.0% during the second quarter. BNP Paribas Financial Markets now owns 21,579 shares of the company’s stock valued at $27,000 after purchasing an additional 7,923 shares in the last quarter. New York State Common Retirement Fund boosted its holdings in Erasca by 39.1% in the 2nd quarter. New York State Common Retirement Fund now owns 37,360 shares of the company’s stock worth $47,000 after buying an additional 10,501 shares during the last quarter. Finally, Sio Capital Management LLC boosted its stake in shares of Erasca by 1.0% in the second quarter. Sio Capital Management LLC now owns 1,369,748 shares of the company’s stock worth $1,740,000 after acquiring an additional 13,562 shares during the last quarter. 67.78% of the stock is owned by hedge funds and other institutional investors.

Erasca Company Profile

Erasca, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene‐driven and immuno‐oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.